Lepirudin

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Synthetic, direct thrombin inhibitor (see below hirudin).

IndicationThis section has been translated automatically.

Heparin-induced thrombocytopenia, other thromboembolic diseases.

Pregnancy/nursing periodThis section has been translated automatically.

No application recommended!

Dosage and method of useThis section has been translated automatically.

Refludan: Initial 0.4 mg/kg bw i.v. as a bolus, then 0.15 mg/kg bw/hour as a continuous infusion over 2-10 days.

Undesirable effectsThis section has been translated automatically.

Frequent bleeding. Rare allergic skin reactions, localized to the injection site.

ContraindicationThis section has been translated automatically.

Hypersensitivity to lepirudine, hirudines or other ingredients. Do not administer in cases of acute bleeding or increased bleeding tendency, advanced kidney function impairment, age over 65 years, pregnancy, lactation.

PreparationsThis section has been translated automatically.

Refludan

Note(s)This section has been translated automatically.

Safety for children has not been proven.

LiteratureThis section has been translated automatically.

  1. Lewis BE et al (2007) Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Expert Rev Cardiovasc Ther 5: 57-68

Authors

Last updated on: 29.10.2020